Harbin Gloria Pharmaceuticals Co.Ltd(002437)
Securities code: 002437 securities abbreviation: Harbin Gloria Pharmaceuticals Co.Ltd(002437) Announcement No.: 2022-002 Harbin Gloria Pharmaceuticals Co.Ltd(002437)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: from January 1, 2021 to December 31, 2021.
2. Expected performance: \uf0f0 turning losses into profits \uf0f0 rising in the same direction ☑ Descending in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to shareholders of listed companies: 40 million yuan ~ 60 million yuan profit: net profit of 400.0491 million yuan, a decrease of 85.00% ~ 90.00% over the same period of last year
Loss after deducting non recurring profit and loss: 10 million yuan ~ 30 million yuan, loss: 305.1466 million yuan, net profit increased by 90.17% ~ 96.72% over the same period of last year
Basic earnings per share: 0.0182 yuan / share ~ 0.0273 yuan / share earnings: 0.1820 yuan / share
2、 Communication with accounting firms
The company has made pre communication with the annual audit accounting firm on major matters related to the performance forecast, and there is no difference between the company and the accounting firm on the financial data related to the performance forecast. This performance forecast has not been pre audited by certified public accountants.
3、 Explanation of performance change reasons
1. The net profit attributable to shareholders of Listed Companies in the same period of last year was 400 million yuan. Among them, the investment income obtained by the company from selling 100% equity of Aonuo (China) Pharmaceutical Co., Ltd. (hereinafter referred to as “Aonuo pharmaceutical”) has an impact on the net profit of 683 million yuan, and this part of the profit and loss is non recurring profit and loss.
2. The net profit attributable to the shareholders of the listed company in the reporting period is expected to be 40 million to 60 million yuan. Excluding the investment income from the sale of Aonuo pharmaceutical in the same period of last year, the company’s performance in the reporting period increased by 114.11% to 121.17% compared with the same period of last year, mainly due to the company’s active response to industrial policies and steady operation, and the sales and business of most products of the company increased compared with the same period of last year, Among them, the business of chronic disease products Menda show and CMO grew rapidly. In addition, during the reporting period, the sales Investment and product R & D of the joint-stock company Guangzhou Yuheng Biotechnology Co., Ltd. after the products are listed have increased significantly, which is expected to affect the company’s net profit of – 40 million yuan to – 50 million yuan in 2021. This part of the income is recurring profit and loss; After excluding the above influencing factors, the net profit attributable to the shareholders of the listed company in the reporting period is expected to be 80 million yuan to 110 million yuan, and the net profit forecast after deducting non recurring profits and losses
Harbin Gloria Pharmaceuticals Co.Ltd(002437) from 10 million yuan to 40 million yuan.
4、 Risk tips
The above data are preliminary calculation results. Please refer to the company’s 2021 annual report for specific financial data. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Harbin Gloria Pharmaceuticals Co.Ltd(002437) board of directors January 29, 2002
